Our Companies
OphtiMed Rx pioneers a revolutionary treatment for dry age-related macular degeneration (AMD), a leading cause of global blindness. Addressing almost half of all blindness cases worldwide, AMD poses significant social and economic burdens. Our innovative drug targets cellular aging (senescence) in AMD, offering a disruptive approach to halt its progression and meeting the urgent need for effective treatments.
Supported by strategic funding from IIA, Private Equity investment by GO Innovation Group, and a Women TechEU grant, we are committed to combatting retinal diseases and preventing vision loss worldwide.
Global Impact and Challenges in Dry AMD Treatment
- Global Burden: AMD accounts for nearly half of all blindness cases globally, resulting in substantial social and economic burdens.
- Current Treatment Gap: Dry AMD, affecting 85-90% of AMD patients, lacks effective therapy due to its intricate and chronic nature, necessitating innovative approaches.
- Advancements Needed: Understanding disease progression (the transition from early to advanced dry AMD or wet AMD) is crucial for effective treatment.
- Socioeconomic Impact: Addressing sight loss in an aging population carries significant health benefits and has profound social and economic implications.
Our Vision and Mission
Focused on developing a groundbreaking treatment for dry AMD, we target the interplay between retinal cellular senescence and disease progression. Backed by a visionary team and strategic partnerships we’re steering toward innovative solutions for Dry AMD.
OphtiMed Rx Solution
- Closing The Treatment Gap: Dry AMD is an aging disease. Cellular senescence plays a key role in the pathogenesis of age-related diseases. Our drug, directed at Retinal Pigment Epithelium (RPE) cell senescence, targets the primary cause of dry AMD, halting disease progression.
- Promising Results: Demonstrated ability to protect RPE cells from senescence and impact key disease characteristics in vivo and in vitro, positioning as a potential solution for early-intermediate dry AMD.
- Future Implications: By developing a therapeutic modality that addresses the root cause of dry AMD, we envision reducing the number of affected individuals and preventing blindness, and curbing the economic burden associated with dry AMD.
This Unique Approach Sets Us Apart From Existing Treatments
Prof. Ayala Pollack, MD, Co-Founder, Medical Advisor & Board Member
World-known retina specialist, researcher, and entrepreneur
Retina Consultant, Tel Aviv Medical Center, and former Chairperson of the Eye Department, Kaplan Medical Center, the Director of the Ophthalmology Eye Research Laboratory, and the Head of Clinical Trials Ophthalmology Unit Kaplan Medical Center.
Dr. Dana Rabinovich, PhD, Co-Founder & CEO
A scientist, biotech executive, and entrepreneur with expertise in drug dev. & diagnostics
Brings 10 years of scientific and management experience in biotechnology, medical R&D, cross-disciplinary projects, and business development. Prior to her position at OphtiMed Rx held management roles in pharma and diagnostics companies, leading R&D in pharmaceutical and diagnostic products.
Mr. Luis Iglesias, Chairman of the BoD
International commercial pharmaceutical, medical devices and diagnostics
Over 35 years in the pharmaceutical and medical device industry, and extensive leadership roles at corporations like Lilly, Abbott, Becton Dickinson, Allergan/Abbvie, and Santen as CEO North America and EMEA.
Scientific Advisory Board
Prof. Anat Loewenstein, MD, Scientific Advisory Board member
orld-known retina specialist and a leader in innovative technologies
Chair, Department of Ophthalmology, Tel Aviv Medical Center, Israel
Prof. Barry Kuppermann, MD, PhD, Scientific Advisory Board member
World-known retina specialist Biotech collaboration and retinal treatment advisor
Chief of the Retina Service at the UCI Gavin Herbert Eye Institute, Irvine, California
Prof. Ayala Pollack, MD, Co-Founder, Medical Advisor & Board Member
World-known retina specialist, researcher, and entrepreneur
Retina Consultant, Tel Aviv Medical Center, and former Chairperson of the Eye Department, Kaplan Medical Center
The Business Opportunity
- Intellectual Property (IP) Landscape: Strong patent portfolio covering compound use and formulation that fosters collaboration and deters competitors. A proactive IP management approach strengthens our defense against infringement, highlighting our commitment to innovation.
- AMD Prevalence: Fast-growing market with millions diagnosed annually. The total global prevalence of AMD in 2020 is estimated at 196 million cases (out of which 176.4 million are dry AMD cases) and it is expected to increase to 288 million cases in 2040 (259.2 million dry AMD).
- Global AMD Market – The Global AMD Market will reach sales of $24.9 billion in 2028 (or $18.7B in 2028 for the 9 major markets: USA, UK, Germany, France, Italy Spain, Australia, Japan, and China). Most of this growth excludes the growth opportunity from addressing The Unmet Need of Dry AMD. Dry AMD products launched before 2028 and new Products post 2028 like OM-301 will drive the growth of the Dry AMD segment.
